Alexandre Bridoux1*, Michel Meyer Samama2,3 and Shaker A Mousa1
1Pharmaceutical Research Institute, USA 2Biomnis Laboratories R&D, France 3Hospital Group Broca-Cauchin-Hôtel-Dieu, FranceFulltext PDF
This review publication highlights chemical characteristics of several direct factor Xa inhibitors that have been recently approved for Atrial Fibrillation (AFIB) and prevention and treatment of Venous Thromboembolic (VTE) disorders. Our goal is to help clinicians clarify the differences between these inhibitors by presenting the chemist and clinician points of view. A summary of the development phase (between the years 2000 to 2010) of the factor Xa inhibitors by the major pharmaceutical companies is reported followed by a focus on some important structure-activity relationships and pharmacological properties of Apixaban, Rivaroxaban, and Edoxaban. To go beyond what is found in the literature, we discuss and rationalize clinical pharmacological properties by reviewing the chemical characteristics of each molecule together with their pharmacological effects.
Direct factor Xa inhibitor; Anticoagulant; Apixaban; Rivaroxaban; Edoxaban
Bridoux A, Samama MM, Mousa SA. Chemical Characteristics of Direct FXa Inhibitors Registered for Atrial Fibrillation. Ann Cardiol Cardiovasc Med. 2019; 3(3): 1028..